Knowledge Distillery

The efficacy of interleukin-6 receptor blockade in hospitalised patients with COVID-19 who are not receiving mechanical ventilation is unclear.

Severe COVID-19 is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus…

NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length…

The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (COVID-19) pneumonia…

The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data…

Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout,…

CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years…

Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines.

Assessment of the safety and efficacy of vaccines against the SARS-CoV-2 in different populations is essential, as is investigation of the efficacy…

COVID-19 is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal…